This topic contains a solution. Click here to go to the answer

Author Question: Firms that emit toxins into the air: a. underproduce because the private cost of production exceeds ... (Read 37 times)

bcretired

  • Hero Member
  • *****
  • Posts: 525
Firms that emit toxins into the air:
 a. underproduce because the private cost of production exceeds the social cost.
  b. overproduce because the social cost of production exceeds the private cost.
  c. produce the same as nonpolluting firms.
  d. produce at the socially optimal amount.

Question 2

All of the following are part of M2 except one. Which is the exception?
 a. Money market deposit accounts
 b. Coins
 c. Traveler's checks
 d. Large-denomination time deposits
  e. Savings deposits



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

wshriver

  • Sr. Member
  • ****
  • Posts: 318
Answer to Question 1

b

Answer to Question 2

d




bcretired

  • Member
  • Posts: 525
Reply 2 on: Jun 30, 2018
YES! Correct, THANKS for helping me on my review


AmberC1996

  • Member
  • Posts: 317
Reply 3 on: Yesterday
Gracias!

 

Did you know?

It is believed that the Incas used anesthesia. Evidence supports the theory that shamans chewed cocoa leaves and drilled holes into the heads of patients (letting evil spirits escape), spitting into the wounds they made. The mixture of cocaine, saliva, and resin numbed the site enough to allow hours of drilling.

Did you know?

Immunoglobulin injections may give short-term protection against, or reduce severity of certain diseases. They help people who have an inherited problem making their own antibodies, or those who are having certain types of cancer treatments.

Did you know?

Between 1999 and 2012, American adults with high total cholesterol decreased from 18.3% to 12.9%

Did you know?

Intradermal injections are somewhat difficult to correctly administer because the skin layers are so thin that it is easy to accidentally punch through to the deeper subcutaneous layer.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library